Dr. Danny Jacobs on taking the helm at OHSU with its transplant program in crisis

Jacobs took over just as the heart transplant program was imploding. The program is now on the mend.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Publication date: Available online 18 February 2020Source: Best Practice &Research Clinical AnaesthesiologyAuthor(s): Andrea De Gasperi, Gregorio Spagnolin, Martina Ornaghi, Laura Petrò, Gianni BiancofioreAbstractNew and extended indications, older age, higher cardiovascular risk, and the long-standing cirrhosis - associated complications mandate specific skills for an appropriate preoperative assessment of the LT candidate. The incidence of cardiac diseases (dysrhythmias, cardiomyopathies, coronary artery disease, valvular heart disease) are increasing among LT recipients: however, no consensus exists among cli...
Source: Best Practice and Research Clinical Anaesthesiology - Category: Anesthesiology Source Type: research
Authors: Boucly A, Savale L, Vuillard C, Turpin M, Jaïs X, Montani D, Humbert M, Sitbon O Abstract Right ventricular failure (RVF) is a common cause of admission to the intensive care unit and its presence is a major prognostic factor in acute pulmonary embolism (PE) and chronic pulmonary hypertension (PH). RVF results from an incapacity of the RV to adapt to an increase in afterload so it can become critical in acute PE and chronic PH. The presence of RVF in cases of acute PE with haemodynamic instability is an indication for thrombolytic therapy. RVF represents the most common cause of death in chronic PH. F...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
AbstractCardiovascular diseases (CVDs) pose a serious threat to human health, which are characterized by high disability and mortality rate globally such as myocardial infarction (MI), atherosclerosis, and heart failure. Although stem cells transplantation and growth factors therapy are promising, their low survival rate and loss at the site of injury are major obstacles to this therapy. Recently, the development of hydrogel scaffold materials provides a new way to solve this problem, which have shown the potential to treat CVD. Among these scaffold materials, environmentally responsive hydrogels have great prospects in re...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Condition:   Acute Rejection of Cardiac Transplant Intervention:   Diagnostic Test: INNOGRAFT Heart Suite Sponsors:   Myway Gentics Srl;   Policlinico San Matteo Pavia Fondazione IRCCS;   Istituto Di Ricerche Farmacologiche Mario Negri Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article describes the studies that have been conducted to date and emphasises that mortality after stem cell transplant (not attributed to CMV end-organ disease) has recently become the first proven indirect effect of CMV now that letermovir has significantly reduced non-relapse deaths.The implications for CMV vaccines are then discussed. Vaccines are already predicted to be highly cost-effective if they can reduce CMV end-organ disease. Health planners should now consider that cost effectiveness is likely to be enhanced further through reduction of the indirect effects of CMV. A prototype scheme for assessing this po...
Source: Antiviral Therapy - Category: Virology Source Type: research
Transplantation of skeletal myoblast sheets is a promising strategy for the treatment of heart failure, and its therapeutic effects have already been proven in both animal disease models and clinical trials. M...
Source: Stem Cell Research and Therapy - Category: Stem Cells Authors: Tags: Research Source Type: research
ConclusionsOur data suggest that GLP-1RA do not affect tacrolimus levels or transplant outcomes in solid organ transplant (SOT) recipients in the short term. GLP-1RA also seem to be as effective in SOT recipients for glycemic control and weight loss as in the non-transplant population with diabetes.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
AbstractThe first successful human heart transplantation was reported on 3 December 1967, by Christiaan Barnard in South Africa. Since then this life ‚Äźsaving procedure has been performed in over 120 000 patients. A limitation to the performance of this procedure is the availability of donor hearts with as many as 20% of patients dying before a donor's heart is available for transplant. Today, hearts for transplantation are procured from indiv iduals experiencing donation after brain death (DBD). Interestingly, this, however, was not always the case as the first heart transplants occurred after circulatory dea...
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: REVIEW ARTICLE Source Type: research
This is the latest in a series of yearly posts in which I suggest areas of development for biotech startups I'd like to see actively developed as a part of the longevity industry in the near future. Today, this year, is a good time to be starting a company focused on the production of a novel therapeutic approach to intervening in the aging process. There is a great deal of funding for seed stage investment, and many compelling projects lacking champions, yet to be carried forward from academia into preclinical development. Numerous scientific and industry crossover conferences are now held every year, at which it is possi...
Source: Fight Aging! - Category: Research Authors: Tags: Investment Source Type: blogs
The Life Extension Advocacy Foundation volunteers here interview Hanadie Yousef of Juvena Therapeutics. Her team is mining the secretions of pluripotent stem cells to find factors that can improve regeneration and stem cell activity in older individuals. Juvena represents one small slice of a broad trend in the regenerative medicine community, many teams building on the past decades of work on stem cell transplantation by seeking to understand and manipulate the cell signaling thought to produce benefits in patients undergoing these first generation therapies. In near all such stem cell therapies, the transplanted cells di...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
More News: Cardiology | Health Management | Heart | Heart Transplant | Men | Pharmaceuticals | Transplant Surgery | Transplants